A direct comparison between lornoxicam and the first marketed specific COX-2 inhibitor in Germany, rofecoxib, with respect to efficacy and tolerability has not yet been performed. The results of ...

Our study examined the effects of celecoxib and rofecoxib on the INR in patients who were stable on warfarin therapy and had multiple comorbidities. We observed both clinically and statistically ...

Rofecoxib and valdecoxib have been withdrawn from the market because they increase the risk of cardiovascular events. To determine whether these drugs and other types of selective cyclooxygenase 2 ...

Triggered by concerns over an increased risk of cardiovascular side effects, Merck announced on 30 September the withdrawal of rofecoxib (Vioxx), its leading drug for the management of rheumatoid ...

El rofecoxib, el antiinflamatorio no esteroide comercializado como Vioxx y retirado del mercado en septiembre de 2004, pudo haber causado una cantidad estimada de entre 88.000 y 140.000 casos de ...